Their article focuses on the increasing safety in using gene editing tools for research and in development of future therapeutics.
Synopsis: "The use of CRISPR/Cas9 a gene editing tool has shown promising results for two types of blood diseases, and clinical trials for other diseases are ongoing. The novel Prime Editing tool has overcome some limitations of the CRISPR/Cas9. National regulations need to be in place to ensure the ethical and responsible application of this emerging technology in patient treatment."
For more details, see www.aftenposten.no/viten/i/8mkxPQ/ett-steg-naermere-tryggere-genredigering (in Norwegian).